Celltrion launches Remsima 카지노 바카라 in Chile, marking first entry into Latin American public markets

[by Kang, In Hyo] Celltrion has successfully established a foothold in a new market with the launch of ‘Remsima SC,’ the world's only subcutaneous (SC) formulation of infliximab, in Chile, marking its first entry into the public market in Latin America. The company announced on December 2 that its Chilean subsidiary has completed the initial supply of Remsima SC, following continued negotiations with the local Public Procurement Agency (CENABAST: Central de Abastecimiento del Sistema Nacional de Servicios de Salud), and has now begun official sales.

Since obtaining product approval for Remsima SC from the Chilean Public Health Institute (ISP) in April 2023, Celltrion has been actively engaging with the government to secure listing under the public insurance system. After approval, Celltrion Chile submitted extensive documentation, including clinical data and published studies, the drug’s official inclusion in the Chilean public insurance system in April of this year. Approximately seven months later, Remsima SC has now been formally launched in the Chilean public market.

In Latin America, pharmaceutical distribution channels operate at an approximately 80:20 ratio between public and private sectors, effectively positioning the public market as the central driver of product sales. According to the company, the accelerated launch was largely driven by strong demand for Remsima 카지노 바카라 from key local stakeholder groups.

In fact, the Chilean Society of Inflammatory Bowel Disease (IBD) formally submitted a letter to the review authority, signed by its president, requesting that Remsima SC be listed under the public insurance program. In addition, the local patient association actively advocated for the product’s inclusion in the government system. The company noted that this proactive support from both medical professionals and patients directly involved in prescribing the product played a decisive role in accelerating the process.

The strong evaluation of Remsima SC's competitiveness by Chilean regulators also played a pivotal role. During discussions on public insurance listing, the ‘New Drug Listing Review Committee’ shortlisted approximately ten drugs for final evaluation, and Remsima SC was the only product to successfully complete the process and secure official listing. This outcome is interpreted as evidence that the market has already recognized the safety, efficacy, and cost-effectiveness of Remsima SC, supported by its growing sales in major global regions, including Europe and North America.

With the initial supply of the product now completed, and given the growing preference among patients for subcutaneous (카지노 바카라) formulations over intravenous (IV) options, significant growth is anticipated in the future. Furthermore, existing products such as Remsima IV, Truxima (rituximab), Herzuma (trastuzumab), and Yuflyma (adalimumab) are already supplied to the Chilean public market, and the company intends to leverage marketing synergies across this portfolio to secure early market dominance.

Celltrion's Latin American subsidiary plans to gradually expand the sales territory for Remsima 카지노 바카라, beginning with its supply in Chile. With the company completing product registration in Brazil, the largest pharmaceutical market in Latin America, in September of this year, the addition of a new supply channel is expected to further accelerate performance growth.

“With the launch of Remsima SC, we anticipate that Chilean patients living with autoimmune diseases will gain broader treatment options and experience an improved quality of life,” said Kang Kyung-doo, Head of Celltrion’s Latin America Region. “Because local clinicians and patient associations underscored the need for Remsima SC during the public insurance review process, which helped to expedite the outcome, we will actively leverage this clear demonstration of market needs and preferences to pursue more aggressive marketing initiatives,” he added.